DOCSLIB.ORG

Antiseptics for Burns (Review)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antiseptics for Burns (Review) Cochrane Database of Systematic Reviews Antiseptics for burns (Review) Norman G, Christie J, Liu Z, Westby MJ, Jefferies JM, Hudson T, Edwards J, Mohapatra DP, Hassan IA, Dumville JC Norman G, Christie J, Liu Z, Westby MJ, Jefferies JM, Hudson T, Edwards J, Mohapatra DP, Hassan IA, Dumville JC. Antiseptics for burns. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD011821. DOI: 10.1002/14651858.CD011821.pub2. www.cochranelibrary.com Antiseptics for burns (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 3 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 OBJECTIVES ..................................... 9 METHODS ...................................... 9 RESULTS....................................... 13 Figure1. ..................................... 14 Figure2. ..................................... 15 Figure3. ..................................... 17 Figure4. ..................................... 18 ADDITIONALSUMMARYOFFINDINGS . 33 DISCUSSION ..................................... 52 AUTHORS’CONCLUSIONS . 55 ACKNOWLEDGEMENTS . 56 REFERENCES ..................................... 56 CHARACTERISTICSOFSTUDIES . 64 DATAANDANALYSES. 161 Analysis 1.1. Comparison 1 Silver dressings versus topical antibiotics, Outcome 1 Wound healing (hazard ratio). 164 Analysis 1.2. Comparison 1 Silver dressings versus topical antibiotics, Outcome 2 Wound healing (mean time to healing). ................................... 165 Analysis 1.3. Comparison 1 Silver dressings versus topical antibiotics, Outcome 3 Wound healing (risk ratio) up to 28 days...................................... 166 Analysis 1.4. Comparison 1 Silver dressings versus topical antibiotics, Outcome 4 Infection (up to 4 weeks or NR). 167 Analysis 1.5. Comparison 1 Silver dressings versus topical antibiotics, Outcome 5 Adverse events (14-28 days). 168 Analysis 1.6. Comparison 1 Silver dressings versus topical antibiotics, Outcome 6 Withdrawals due to adverse events (21 daysorNR). .................................. 169 Analysis 1.7. Comparison 1 Silver dressings versus topical antibiotics, Outcome 7 Pain at dressing change (up to 28 days or NR)...................................... 169 Analysis 1.8. Comparison 1 Silver dressings versus topical antibiotics, Outcome 8 Pain (time/follow-up not specified). 170 Analysis 1.9. Comparison 1 Silver dressings versus topical antibiotics, Outcome 9 Mortality (21 days or NR). 171 Analysis 1.10. Comparison 1 Silver dressings versus topical antibiotics, Outcome 10 Resource use (number of dressings) (upto28daysorNR).. 172 Analysis 1.11. Comparison 1 Silver dressings versus topical antibiotics, Outcome 11 Costs (21 days or NR). 173 Analysis 1.12. Comparison 1 Silver dressings versus topical antibiotics, Outcome 12 Cost-effectiveness/wound healed (21 days). .................................... 174 Analysis 2.1. Comparison 2 Honey versus topical antibiotics, Outcome 1 Wound healing (hazard ratio). 174 Analysis 2.2. Comparison 2 Honey versus topical antibiotics, Outcome 2 Wound healing (risk ratio) (up to 60 days). 175 Analysis 2.3. Comparison 2 Honey versus topical antibiotics, Outcome 3 Wound healing (mean time to healing). 176 Analysis 2.4. Comparison 2 Honey versus topical antibiotics, Outcome 4 Incident infection (up to 24 days). 177 Analysis 2.5. Comparison 2 Honey versus topical antibiotics, Outcome 5 Persistent positive swabs (up to 21 days). 178 Analysis 2.6. Comparison 2 Honey versus topical antibiotics, Outcome 6 Adverse events (time points between 21 days and 6weeks). ................................... 179 Analysis 3.1. Comparison 3 Aloe vera vs topical antibiotics, Outcome 1 Wound healing (mean time to healing). 180 Analysis 3.2. Comparison 3 Aloe vera vs topical antibiotics, Outcome 2 Infection (time points between 14 days and 2 months). ................................... 181 Analysis 4.1. Comparison 4 Iodine-based treatments versus topical antibiotics, Outcome 1 Wound healing (mean time to healing). ................................... 182 Analysis 5.1. Comparison 5 Silver-based antiseptics versus non-antimicrobial, Outcome 1 Wound healing (mean time to healing). ................................... 182 Antiseptics for burns (Review) i Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 5.2. Comparison 5 Silver-based antiseptics versus non-antimicrobial, Outcome 2 Positive swab (21 days). 183 Analysis 6.1. Comparison 6 Honey versus non-antibacterial dressing, Outcome 1 Wound healing (hazard ratio). 184 Analysis 6.2. Comparison 6 Honey versus non-antibacterial dressing, Outcome 2 Wound healing (mean time to healing). ................................... 184 Analysis 6.3. Comparison 6 Honey versus non-antibacterial dressing, Outcome 3 Persistent positive swabs (up to 30 days). .................................... 185 Analysis 7.1. Comparison 7 Chlorhexadine versus non-antibacterial dressing, Outcome 1 Wound healing (mean time to healing). ................................... 186 Analysis 7.2. Comparison 7 Chlorhexadine versus non-antibacterial dressing, Outcome 2 Infection (up to 30 days). 187 Analysis 8.1. Comparison 8 Iodine-based antiseptics versus non-antibacterial treatments, Outcome 1 Wound healing (mean timetohealing).. ... ... ... ... ... ... ... ... ... ... .. 187 Analysis 8.2. Comparison 8 Iodine-based antiseptics versus non-antibacterial treatments, Outcome 2 Costs (duration 18 days+)..................................... 188 Analysis 9.1. Comparison 9 Cerium nitrate versus non antibacterial treatment, Outcome 1 Mortality (short-term or unclear). ................................... 189 ADDITIONALTABLES. 189 APPENDICES ..................................... 225 WHAT’SNEW..................................... 234 CONTRIBUTIONSOFAUTHORS . 234 DECLARATIONSOFINTEREST . 235 SOURCESOFSUPPORT . 235 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 236 INDEXTERMS .................................... 236 Antiseptics for burns (Review) ii Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Antiseptics for burns Gill Norman1, Janice Christie1, Zhenmi Liu1, Maggie J Westby1, Jayne M Jefferies2, Thomas Hudson2, Jacky Edwards3, Devi Prasad Mohapatra4, Ibrahim A Hassan5, Jo C Dumville1 1Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. 2Evidence Information Services, National Institute for Health and Care Excellence (NICE), Manchester, UK. 3Burn Centre, Acute Block, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK. 4Plastic Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. 5Microbiology, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK Contact address: Gill Norman, Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester Academic Health Science Centre, Jean McFarlane Building, Oxford Road, Manchester, M13 9PL, UK. [email protected]. Editorial group: Cochrane Wounds Group. Publication status and date: Edited (no change to conclusions), published in Issue 11, 2017. Citation: Norman G, Christie J, Liu Z, Westby MJ, Jefferies JM, Hudson T, Edwards J, Mohapatra DP, Hassan IA, Dumville JC. Antiseptics for burns. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD011821. DOI: 10.1002/14651858.CD011821.pub2. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Burn wounds cause high levels of morbidity and mortality worldwide. People with burns are particularly vulnerable to infections; over 75% of all burn deaths (after initial resuscitation) result from infection. Antiseptics are topical agents that act to prevent growth of micro-organisms. A wide range are used with the intention of preventing infection and promoting healing of burn wounds. Objectives To assess the effects and safety of antiseptics for the treatment of burns in any care setting. Search methods In September 2016 we searched the Cochrane Wounds Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid MEDLINE (In-Process & Other Non-Indexed Citations), Ovid Embase, and EBSCO CINAHL. We also searched three clinical trials registries and references of included studies and relevant systematic reviews. There were no restrictions based on language, date of publication or study setting. Selection criteria We included randomised controlled trials (RCTs) that enrolled people with any burn wound and assessed the use of a topical treatment with antiseptic properties. Data collection and analysis Two review authors independently performed study selection, risk of bias assessment and data extraction. Antiseptics for burns (Review) 1 Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Main results We included 56 RCTs with 5807 randomised participants. Almost all trials had poorly reported methodology, meaning that it is unclear whether they were at high risk of bias. In many cases the primary review outcomes, wound healing and infection,
Load more

Recommended publications
  • Airgid - Instructions for Use Im3 Airgid Is a Gelatin Collagen Sponge of Hemostatic Action to Which 5 % Colloidal Silver Is Added
    Airgid - Instructions for Use iM3 Airgid is a gelatin collagen sponge of hemostatic action to which 5 % colloidal silver is added. It facilitates optimum wound treatment when applied to a surgical cavity and can be cut to the required size to fit smaller wound cavities. The evenly porous foam structure absorbs its own weight in blood several times over, promotes thrombocyte aggregation due to the large surface and fills the wound cavity. The plug thus formed has a constant volume, fits snugly and stabilises blood coagulum. This prevents the formation of fissures and secondary cavities which, without iM3 Airgid, could form by contraction of the blood coagulum and trigger infection due to the invasion of contaminated saliva. Does not block the callus formation. iM3 Airgid remains in the wound and completely absorbed within 3-4 weeks. The addition of colloidal silver has an antimicrobial effect and does not develop any body resistance. Unlike other potential antimicrobial additives, colloidal silver cannot be washed away from the sponge so that its insolubility produces a long-lasting depot effect. Gamma-ray sterilisation process finalizes the manufacturing cycle of the product. Composition: One iM3 Airgid Small Animal (10 × 10 × 10 mm) contains: Hardened gelatine Ph. Eur. 13.85 mg. Colloid silver Ph. Eur. 0.73 mg. One iM3 Airgid Equine (20 × 20 × 20 mm) contains: Hardened gelatine Ph. Eur. 110.8 mg. Colloid silver Ph. Eur. 5.8 mg. Indications: • Socket extraction as part of one or two-stage implant placement. • The general treatment of alveoli and wound cavities, e.g. after cystostomies, apical amputations, maxillary sinus perforations, following surgical removal of tumours or retained teeth.
    [Show full text]
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds
    Supplementary Materials In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds Karolina Dydak 1, Adam Junka 1,*, Agata Dydak 2, Malwina Brożyna 1, Justyna Paleczny 1, Karol Fijalkowski 3, Grzegorz Kubielas 4, Olga Aniołek 5 and Marzenna Bartoszewicz 1 1 Department of Pharmaceutical Microbiology and Parasitology, Medical University of Wroclaw, 50-556 Wroclaw, Poland; [email protected] (K.D.); [email protected] (M.B.); [email protected] (J.P.); [email protected] (M.B.) 2 Faculty of Biological Sciences, University of Wroclaw, 51-148 Wroclaw, Poland; [email protected] 3 Department of Microbiology and Biotechnology, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, Szczecin, Piastow 45, 70-311 Szczecin, Poland; [email protected] 4 Faculty of Health Sciences, Wroclaw Medical University, 50-996 Wroclaw, Poland; [email protected] 5 Faculty of Medicine, Lazarski University, 02-662 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-889229341 Citation: Dydak, K.; Junka, A.; Dydak, A.; Brożyna, M.; Paleczny, J.; Abstract: Local administration of antiseptics is required to prevent and fight against biofilm-based Fijalkowski, K.; Kubielas, G.; infections of chronic wounds. One of the methods used for delivering antiseptics to infected wounds Aniołek, O.; Bartoszewicz, M. In is the application
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,039,940 Perrault Et Al
    US0060399.40A United States Patent (19) 11 Patent Number: 6,039,940 Perrault et al. (45) Date of Patent: Mar. 21, 2000 54) INHERENTLY ANTIMICROBIAL 5,563,056 10/1996 Swan et al.. QUATERNARY AMINE HYDROGEL WOUND 5,599.321 2/1997 Conway et al.. DRESSINGS 5,624,704 4/1997 Darouiche et al.. 5,670.557 9/1997 Dietz et al.. 75 Inventors: James J. Perrault, Vista, Calif.; 5,674.561 10/1997 Dietz et al.. Cameron G. Rouns, Pocatello, Id. 5,800,685 9/1998 Perrault. FOREIGN PATENT DOCUMENTS 73 Assignee: Ballard Medical Products, Draper, Utah 92/06694 4/1992 WIPO. WO 97/14448 4/1997 WIPO. 21 Appl. No.: 09/144,727 OTHER PUBLICATIONS 22 Filed: Sep. 1, 1998 I. I. Raad, “Vascular Catheters Impregnated with Antimi crobial Agents: Present Knowledge and Future Direction,” Related U.S. Application Data Infection Control and Hospital Epidemiology, 18(4): 63 Continuation-in-part of application No. 08/738,651, Oct. 28, 227–229 (1997). 1996, Pat. No. 5,800,685. R. O. Darouiche, H. Safar, and I. I. Raad, “In Vitro Efficacy of Antimicrobial-Coated Bladder Catheters in Inhibiting 51) Int. Cl." .......................... A61K31/785; A61F 13/00 Bacterial Migration along Catheter Surface,” J. Infect. Dis., 52 U.S. Cl. ..................................... 424/78.06; 424/78.08; 176: 1109-12 (1997). 424/78.35; 424/78.37; 424/443; 424/445 W. Kohen and B. Jansen, “Polymer Materials for the Pre 58 Field of Search ..................................... 424/443, 445, vention of Catheter-related Infections.” Zbl Bakt., 283: 424/78.06, 78.07, 78.08, 78.35, 78.37 175-186 (1995).
    [Show full text]
  • Ethacridine Lactate Monohydrate
    Ethacridine Lactate Monohydrate sc-205315 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Ethacridine Lactate Monohydrate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY: ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C15-H15-N3-O.C3H6O3, "lactic acid, compd. with 6.9-diamino-2-ethoxyacridine (1:1)", "6, 9-acridinediamine, 2-ethoxy-, 2-hydroxypropanoate (1:1)", "acridine, 6, 9-diamino-2-ethoxy-, compd. with lactic acid (1:1)", "acridine, 6, 9-diamino-2-ethoxy-, monolactate", "2, 5-diamino-7-ethoxyacridine lactate", "6, 9-diamino-2-ethoxyacridine lactate", "6, 9-diamino-2-oxyethylacridine lactate", "2-ethoxy-6, 9-diaminoacridine lactate", "2-ethoxy-6, 9-diaminoacridinium lactate", Acrinol, Acrolactine, Ethodin, Flavitrol, Metifex, Rimaon, Rivanol, Rivinol, Vucine, "antiseptic/ disinfectant" Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 CANADIAN WHMIS SYMBOLS 1 of 7 EMERGENCY OVERVIEW RISK May cause SENSITISATION by skin contact. Irritating to eyes, respiratory system and skin. Toxic to aquatic organisms. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be damaging to the health of the individual. ! Acridines may cause nausea, vomiting, and digestive tract irritation.
    [Show full text]
  • Identification of Drug Candidates That Enhance Pyrazinamide Activity from a Clinical Drug Library
    bioRxiv preprint doi: https://doi.org/10.1101/113704; this version posted March 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library Hongxia Niub, a, Chao Mac, Peng Cuid, Wanliang Shia, Shuo Zhanga, Jie Fenga, David Sullivana, Bingdong Zhu b, Wenhong Zhangd, Ying Zhanga,d* a Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA b Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China c College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China d Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China *Correspondence: Ying Zhang, E-Mail: [email protected] Tuberculosis (TB) remains a leading cause of morbidity and mortality globally despite the availability of the TB therapy. 1 The current TB therapy is lengthy and suboptimal, requiring a treatment time of at least 6 months for drug susceptible TB and 9-12 months (shorter Bangladesh regimen) or 18-24 months (regular regimen) for multi-drug-resistant tuberculosis (MDR-TB). 1 The lengthy therapy makes patient compliance difficult, which frequently leads to emergence of drug-resistant strains. The requirement for the prolonged treatment is thought to be due to dormant persister bacteria which are not effectively killed by the current TB drugs, except rifampin and pyrazinamide (PZA) which have higher activity against persisters.
    [Show full text]
  • Application of Rotating Magnetic Fields Increase the Activity of Antimicrobials Against Wound Biofilm Pathogens
    www.nature.com/scientificreports OPEN Application of Rotating Magnetic Fields Increase the Activity of Antimicrobials Against Wound Received: 6 June 2017 Accepted: 16 November 2017 Bioflm Pathogens Published: xx xx xxxx A. F. Junka1, R. Rakoczy2, P. Szymczyk3, M. Bartoszewicz1, P. P. Sedghizadeh4 & K. Fijałkowski 5 Infective complications are a major factor contributing to wound chronicity and can be associated with signifcant morbidity or mortality. Wound bacteria are protected in bioflm communities and are highly resistant to immune system components and to antimicrobials used in wound therapy. There is an urgent medical need to more efectively eradicate wound bioflm pathogens. In the present work, we tested the impact of such commonly used antibiotics and antiseptics as gentamycin, ciprofoxacin, octenidine, chlorhexidine, polihexanidine, and ethacridine lactate delivered to Staphylococcus aureus and Pseudomonas aeruginosa bioflms in the presence of rotating magnetic felds (RMFs) of 10–50 Hz frequency and produced by a customized RMF generator. Fifty percent greater reduction in bioflm growth and biomass was observed after exposure to RMF as compared to bioflms not exposed to RMF. Our results suggest that RMF as an adjunct to antiseptic wound care can signifcantly improve antibioflm activity, which has important translational potential for clinical applications. Wounds, especially chronic ones and protracted with infective complications, become an increasing burden for patients and healthcare systems and lead to signifcant deterioration of life or, if untreated appropriately, to death1. Te infective complication of wound ulcerations of virtually each etiology: venous, arterial, diabetic, neoplastic, bedsores, or of burn origin impedes or stops the process of wound healing and is responsible for persistence or chronicity of a wound.
    [Show full text]
  • New Spectrophotometric Methods for Estimation of Ethacridine Lactate in Pharmaceutical Formulations
    Available online a t www.pelagiaresearchlibrary.com Pelagia Research Library Der Chemica Sinica, 2011, 2 (1): 15-20 ISSN: 0976-8505 CODEN (USA) CSHIA5 New spectrophotometric methods for estimation of Ethacridine lactate in pharmaceutical formulations 1* 1 1 Aziz Unnisa , B. Hemalatha , N. V. Chenchu Lakshmi and D. Srinivasulu 2 1K.V.S.R Siddhartha College of Pharmaceutical Sciences, Vijayawada, A. P., India 2Andhra University, Vishakapatnam, A. P., India ______________________________________________________________________________ ABSTRACT Ethacridine lactate is an antiseptic in solutions of 0.1%; it is also used as an agent for second trimester abortion. Upto 150ml of 0.1% solution is instilled extra amniotically using a foley catheter. Three simple and sensitive spectrophotometric methods (Method A, Method B and Method C) were developed for the estimation of Ethacridine lactate in pharmaceutical formulations. These methods are based on the oxidative coupling of Eathacridine Lactate with 2,2’-bipyridyl, Bathophenanthroline and 2,4,6-tripyridyl- s-triazine in the presence of Fe(III) to form coloured chromophores which can be estimated at absorption maximums of 450nm, 600 and 540 respectively.. Method A, Method B and Method C obey the beers law in the concentration range of 5-25 µg/ml, 4-24 µg/ml and 6-26µg/ml respectively. The methods were validated for use in routine quality control of Ethacridine lactate in pharmaceutical formulations. Interference studies were conducted and it was found that the common excipients usually present in dosage forms do not interfere in the proposed methods. The optical characteristics, regression analysis data and precision of the methods were calculated. The accuracy of the methods was evaluated by estimating the amount of Ethacridine Lactate in previously analyzed samples to which known amounts of Ethacridine Lactate was spiked.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Risks to Health and the Environment Related to the Use of Mercury Products
    Ref. Ares(2015)4242228 - 12/10/2015 Risks to Health and the Environment Related to the Use of Mercury Products Final Report prepared for The European Commission, DG Enterprise by Risk & Policy Analysts Limited, Farthing Green House, 1 Beccles Road, Loddon, Norfolk, NR14 6LT Tel: 01508 528465 Fax: 01508 520758 Email: [email protected] Web: www.rpaltd.co.uk RPA REPORT - ASSURED QUALITY Project: Ref/Title J372/Mercury Approach: In accordance with the Contract, Scoping Meeting with the Commission and associated discussions Report Status: Final Report Authors: Dr P Floyd & P Zarogiannis, RPA Dr M Crane, Crane Consultants Prof S Tarkowski, Nofer Institute of Occupational Medicine (Poland) Prof V Bencko, Charles University of Prague Approved for Issue by: Ms M Postle, Director Date: 9 August, 2002 If printed by RPA, this report will be on chlorine free, 100% recycled paper. Risk & Policy Analysts EXECUTIVE SUMMARY Overview Mercury and its compounds are hazardous materials which may pose risks to people and to the environment. This report presents an assessment of the risks associated with the use of mercury in a range of products. The key requirements of the study were: • to identify usage of mercury in dental amalgam, batteries, measuring instruments (such as thermometers and manometers), lighting, other electrical components and other lesser uses; • to review data used to evaluate the toxicity of mercury and mercury compounds to humans and to the environment; • to derive predicted environmental concentrations (PECs) associated with use of the products under consideration and compare with those associated with other sources of mercury; and • to characterise the associated risks.
    [Show full text]
  • Survey of Mercury and Mercury Compounds
    Survey of mercury and mercury compounds Part of the LOUS-review Environmental Project No. 1544, 2014 Title: Authors and contributors: Survey of mercury and mercury compounds Jakob Maag Jesper Kjølholt Sonja Hagen Mikkelsen Christian Nyander Jeppesen Anna Juliana Clausen and Mie Ostenfeldt COWI A/S, Denmark Published by: The Danish Environmental Protection Agency Strandgade 29 1401 Copenhagen K Denmark www.mst.dk/english Year: ISBN no. 2014 978-87-93026-98-8 Disclaimer: When the occasion arises, the Danish Environmental Protection Agency will publish reports and papers concerning research and development projects within the environmental sector, financed by study grants provided by the Danish Environmental Protection Agency. It should be noted that such publications do not necessarily reflect the position or opinion of the Danish Environmental Protection Agency. However, publication does indicate that, in the opinion of the Danish Environmental Protection Agency, the content represents an important contribution to the debate surrounding Danish environmental policy. While the information provided in this report is believed to be accurate, the Danish Environmental Protection Agency disclaims any responsibility for possible inaccuracies or omissions and consequences that may flow from them. Neither the Danish Environmental Protection Agency nor COWI or any individual involved in the preparation of this publication shall be liable for any injury, loss, damage or prejudice of any kind that may be caused by persons who have acted based on their understanding of the information contained in this publication. Sources must be acknowledged. 2 Survey of mercury and mercury compounds Contents Preface ...................................................................................................................... 5 Summary and conclusions ......................................................................................... 7 Sammenfatning og konklusion ................................................................................ 14 1.
    [Show full text]